Methods for treating hair loss disorders

Patent metadata

Field	Value
Publication number	US-9763866-B2
Application number	US-201615066554-A
Country	US
Kind code	B2
Filing date	Mar 10, 2016
Priority date	Nov 2, 2010
Publication date	Sep 19, 2017
Grant date	Sep 19, 2017

Abstract

The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

First claim

What is claimed:

1. A method of treating a hair-loss disorder in a mammalian subject in need thereof, the method comprising administering to the subject an effective amount of an inhibitor of Janus Kinase (Jak) 1, Jak2, or Jak3, wherein said inhibitor is VX-509 and wherein the hair-loss disorder is selected from the group consisting of androgenetic alopecia, alopecia areata, telogen effluvium, tinea capitis, hypotrichosis, and hereditary hypotrichosis simplex.

2. The method of claim 1 , wherein the alopecia areata is alopecia totalis.

3. The method of claim 1 wherein the subject is a human.

4. The method of claim 3 wherein the hair loss-disorder is androgenetic alopecia.

5. The method of claim 1 wherein the hair loss-disorder is alopecia areata.

6. The method of claim 1 , wherein administering to the subject occurs by a route selected from the group consisting of subcutaneous injection, intra-muscular injection, intra-peritoneal injection, intravenous injection, an infusion, oral, nasal, topical, intradermal, inhalation, transdermal, transmucosal, rectal and any combinations thereof.

7. The method of claim 1 , wherein VX-509 is administered to the subject in a pharmaceutical composition selected from the group consisting of solution, suspension, capsule, tablet, pill, troche, nasal spray, suppository, ointment, salve, gel, and cream.

8. The method of claim 1 , wherein VX-509 is contained in a topical pharmaceutical composition at a concentration selected from the group consisting of about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, or about 3.0%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, and about 10%.

9. The method of claim 1 , wherein the effective amount of VX-509 administered to the subject is selected from the group consisting of about 1 mg/kg body weight, about 1.5 mg/kg body weight, about 2 mg/kg body weight, about 2.5 mg/kg body weight, about 3 mg/kg body weight, about 3.5 mg/kg body weight, about 4 mg/kg body weight, about 4.5 mg/kg body weight, about 5 mg/kg body weight, about 5.5 mg/kg body weight, about 6 mg/kg body weight, about 6.5 mg/kg body weight, about 7 mg/kg body weight, about 7.5 mg/kg body weight, about 8 mg/kg body weight, about 9.5 mg/kg body weight, about 10 mg/kg body weight, about 10.5 mg/kg body weight, about 11.0 mg/kg body weight, about 11.5 mg/kg body weight, about 12 mg/kg body weight, about 12.5 mg/kg body weight, about 13 mg/kg body weight, about 13.5 mg/kg body weight, about 14 mg/kg body weight, about 14.5 mg/kg body weight, about 15 mg/kg body weight, about 15.5 mg/kg body weight, about 16 mg/kg body weight, about 16.5 mg/kg body weight, about 17 mg/kg body weight, about 17.5 mg/kg body weight, about 18 mg/kg body weight, about 19.5 mg/kg body weight, about 20 mg/kg body weight, about 21.5 mg/kg body weight, about 22 mg/kg body weight, about 22.5 mg/kg body weight, about 23 mg/kg body weight, about 23.5 mg/kg body weight, about 24 mg/kg body weight, about 24.5 mg/kg body weight, about 25 mg/kg body weight, about 25.5 mg/kg body weight, about 26 mg/kg body weight, about 26.5 mg/kg body weight, about 27 mg/kg body weight, about 27.5 mg/kg body weight, about 28 mg/kg body weight, about 29.5 mg/kg body weight, and about 30 mg/kg body weight.

10. The method of claim 1 , wherein administering occurs daily, weekly, twice weekly, monthly, twice monthly, yearly, 1 time per week, 2 times per week, 3 times per week, 4 times per week, 5 times per week, 6 times per week, 7 times per week, 8 times per week, 9 times per week, 10 times per week, 11 times per week, 12 times per week, 13 times per week, or 14 times per week.

11. The method of claim 1 , wherein administering to the subject occurs for at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 8 weeks, at least 12 weeks, or at least 16 weeks.

12. The method of claim 1 , wherein the alopecia areata is alopecia universalis.

13. The method of claim 1 , wherein the alopecia areata is patchy alopecia areata.

14. A method for inducing hair growth in a subject, the method comprising (a) administering to the subject an effective amount of a Jak1, Jak2, or Jak3 inhibitor, wherein said inhibitor is VX-509, thereby inducing hair growth in the subject and wherein the subject suffers from a hair-loss disorder selected from the group consisting of androgenetic alopecia, alopecia areata, telogen effluvium, tinea capitis, hypotrichosis, and hereditary hypotrichosis simplex.

15. The method of claim 14 , wherein the alopecia areata is alopecia totalis.

16. The method of claim 14 wherein the hair loss-disorder is androgenetic alopecia.

17. The method of claim 14 wherein the hair loss-disorder is alopecia areata.

18. The method of claim 14 , wherein administering to the subject occurs by a route selected from the group consisting of subcutaneous injection, intra-muscular injection, intra-peritoneal injection, intravenous injection, an infusion, oral, nasal, topical, intradermal, inhalation, transdermal, transmucosal, rectal, and any combinations thereof.

19. The method of claim 14 , wherein VX-509 is administered to the subject in a pharmaceutical composition selected from the group consisting of solution, suspension, capsule, tablet, pill, troche, nasal spray, suppository, ointment, salve, gel, and cream.

20. The method of claim 14 , wherein VX-509 is contained in a topical pharmaceutical composition at a concentration selected from the group consisting of about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, about 1.1%, about 1.2%, about 1.3%, about 1.4%, about 1.5%, about 1.6%, about 1.7%, about 1.8%, about 1.9%, about 2.0%, about 2.1%, about 2.2%, about 2.3%, about 2.4%, about 2.5%, about 2.6%, about 2.7%, about 2.8%, about 2.9%, or about 3.0%, about 3.5%, about 4%, about 4.5%, about 5%, about 5.5%, about 6%, about 6.5%, about 7%, about 7.5%, about 8%, about 8.5%, about 9%, about 9.5%, and about 10%.

21. The method of claim 14 , wherein the effective amount of VX-509 administered to the subject is selected from the group consisting of about 1 mg/kg body weight, about 1.5 mg/kg body weight, about 2 mg/kg body weight, about 2.5 mg/kg body weight, about 3 mg/kg body weight, about 3.5 mg/kg body weight, about 4 mg/kg body weight, about 4.5 mg/kg body weight, about 5 mg/kg body weight, about 5.5 mg/kg body weight, about 6 mg/kg body weight, about 6.5 mg/kg body weight, about 7 mg/kg body weight, about 7.5 mg/kg body weight, about 8 mg/kg body weight, about 9.5 mg/kg body weight, about 10 mg/kg body weight, about 10.5 mg/kg body weight, about 11.0 mg/kg body weight, about 11.5 mg/kg body weight, about 12 mg/kg body weight, about 12.5 mg/kg body weight, about 13 mg/kg body weight, about 13.5 mg/kg body weight, about 14 mg/kg body weight, about 14.5 mg/kg body weight, about 15 mg/kg body weight, about 15.5 mg/kg body weight, about 16 mg/kg body weight, about 16.5 mg/kg body weight, about 17 mg/kg body weight, about 17.5 mg/kg body weight, about 18 mg/kg body weight, about 19.5 mg/kg body weight, about 20 mg/kg body weight, about 21.5 mg/kg body we

Assignees

• Univ Columbia

Inventors

• Christiano Angela M
• Clynes Raphael

Classifications

• A61K31/437

  the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline · CPC title

• A61K31/137

  Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone} · CPC title

• A61K8/64

  Proteins; Peptides; Derivatives or degradation products thereof · CPC title

• A61Q7/00

  Preparations for affecting hair growth · CPC title

• A61K31/5377

  not condensed and containing further heterocyclic rings, e.g. timolol · CPC title